Development of antimetastatic drugs by targeting tumor sialic acids

Scientia Pharmaceutica

Volumn 80, Issue 3, 2012, Pages 497-508

  Lu, Da Yong ^a   Lu, Ting Ren ^a   Wu, Hong Ying ^a  

^a SHANGHAI UNIVERSITY   (China)

Author keywords

Anticancer therapy; Cancer biology; Cancer chemotherapy; Glycobiology; Glycosylation; Neoplasm metastases; Neoplasm targeting; Neuraminidic acids; Probimane; Sialic acid; Sialylation

Indexed keywords

AL 10; ANTIMETASTATIC AGENT; CD22 ANTIGEN; CHLORMETHINE; CISPLATIN; GLYCOLIPID; GLYCOPROTEIN; PROBIMANE; SIALIC ACID; SIALYL GLYCAN; UNCLASSIFIED DRUG;

CANCER INHIBITION; CELL METABOLISM; COLORIMETRY; DRUG MECHANISM; METASTASIS INHIBITION; NONHUMAN; REVIEW; TUMOR CELL;

EID: 84866513086     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1205-01     Document Type: Review

References (54)

1. Varmus H. The new era in cancer research. Science. 2006; 312: 1162-1165. http://dx.doi.org/10.1126/science.1126758.
2. Spoon MB. The war on cancer. Lancet. 1996; 347: 1377-1381. http://dx.doi.org/10.1016/S0140-6736(96)91015-6.
3. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Smigal C, Thun MJ. Cancer Statistics 2006. Cancer J Clin. 2006; 56: 106-130. http://dx.doi.org/10.3322/canjclin.56.2.106.
4. Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 1-18. http://dx.doi.org/10.1146/annurev.med.57.121304.131306.
5. Dong F, Budhu AS, Wang XW. Translating the metastasis paradigm from scientific theory to clinical oncology. Clin Cancer Res. 2009; 15: 2588-2593. http://dx.doi.org/10.1158/1078-0432.CCR-08-2356.
6. Lu DY, Lu TR. Antimetastatic activities and mechanisms of Bisdioxopiperazine compounds. Anticancer Agents Med Chem. 2010; 10: 564-570. http://www.ncbi.nlm.nih.gov/pubmed/20950258.
7. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjugate J. 1997; 14: 569-576. http://dx.doi.org/10.1023/A:1018580324971.
8. Scanlin TF, Click MC. Terminal glycosylation and disease: influence on cancer and cyctic fibrosis. Glycoconjugate J. 2000; 17: 617-626. http://dx.doi.org/10.1023/A:1011034912226.
9. nd edition. Cold Spring Harbor (NY: Cold Spring Harbor Laboratory Press), 2009, Chapter 44.
10. Lu DY, Lu TR, Wu HY. Antimetastatic therapy targeting aberrant sialylation profiles in cancer cells. Drug Therapy Studies. 2011; 1: e12. http://dx.doi.org/10.4081/dts.2011.e12.
11. Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Investigation. 2007; 87: 851-857. http://dx.doi.org/10.1038/labinvest.3700656.
12. Varki A. Sialic acids in human health and disease. Trend Mol Med. 2008; 14: 351-360. http://dx.doi.org/10.1016/j.molmed.2008.06.002.
13. nd edition. Cold Spring Harbor (NY: Cold Spring Harbor Laboratory Press), 2009, Chapter 14.
14. Taurumi KI, Dawes ML. Serum sialic acid levels in mice with neoplasms. Cancer Res. 1958; 18: 575-577. http://www.ncbi.nlm.nih.gov/pubmed/13547052.
15. Kimura A, Nagai Y, Taurumi KI, Kawashima Y, Sato H. Hexosamine and sialic acid contents in cells. Nature. 1961; 191: 596-. http://dx.doi.org/10.1038/191596a0.
16. Yogeeswaran G, Salk PL. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science. 1981; 212: 1514-1516. http://dx.doi.org/10.1126/science.7233237.
17. X antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993; 53: 3632-3637. http://www.ncbi.nlm.nih.gov/pubmed/8101764.
18. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconjugate J. 1997; 14: 577-583. http://dx.doi.org/10.1023/A:1018532409041.
19. Terashima S, Takano Y, Ohori T, Kanno T, Kimura T, Motoki R, Kawaguchi T. Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer. Surg Today. 1998; 20: 682-686. http://dx.doi.org/10.1007/BF02484612.
20. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. sTn and prognosis in breast cancer. Oncology. 2001, 64: 299-305. http://dx.doi.org/10.1159/000055337.
21. Angata T, Varki A. Chemical diversity in the sialic acids and related α-keto acids: an evolutionary perspective. Chem Rev. 2002; 102: 439-469. http://dx.doi.org/10.1021/cr000407m.
22. Kijima-Suda I, Miyamoto Y, Toyoshima S, Itoh M, Osawa T. Inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid: nucleoside conjugate having sialyltransferase inhibiting activity. Cancer Res. 1986; 46: 858-862. http://www.ncbi.nlm.nih.gov/pubmed/3753583.
23. Kijima-Suda I, Miyazawa T, Itoh M, Toyoshima S, Osawa T. Possible mechanism of inhibition of experimental pulmonary metastasis of mouse colon adenocarcinoma 26 sublines by a sialic acid: nucleoside conjugate. Cancer Res. 1988; 48: 3728-3732. http://www.ncbi.nlm.nih.gov/pubmed/3288333.
24. Radin N, Inokuchi J. Glucosphingolipids as sites of action in the chemotherapy of cancer. Biochem Pharmacol. 1988; 37: 2879-2886. http://dx.doi.org/10.1016/0006-2952(88)90271-7.
25. Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW. A phase I study of Swainsonine in patients with advanced malignancies. Cancer Res. 1994; 54: 1450-1457. http://www.ncbi.nlm.nih.gov/pubmed/8137247.
26. Fuster MM, Brown JR, Wang LC, Esko JD. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res. 2003; 63: 2775-2781. http://www.ncbi.nlm.nih.gov/pubmed/12782582.
27. Freeze HH. Genetic defects in the human glycome. Nat Rev Genet. 2006; 7: 537-551. http://dx.doi.org/10.1038/nrg1894.
28. Pilobello KT, Mahal LK. Deciphering the glycocode: The complexity and analytical challenge of glycomics. Curr Opin Chem Biol. 2007; 11: 300-305. http://dx.doi.org/10.1016/j.cbpa.2007.05.002.
29. nd edition. Cold Spring Harbor (NY: Cold Spring Harbor Laboratory Press), 2009, Chapter 48.
30. Naka R, Kamoda S, Ishizuka A, Kinoshita M, Kakehi K. Analysis of total N-Glycans in cell membrane fractions of cancer cells using a combination of serotonin affinity chromatography and normal phase chromatography. J Proteome Res. 2006; 5: 88-97. http://dx.doi.org/10.1021/pr0502976.
31. Lin SY, Chen YY, Fan YY, Lin CW, Chen ST, Wang AHJ, Khoo KH. Precise mapping of increased sialylation pattern and the expression of acute phase proteins accompanying murine tumor progression in BALB/c mouse by integrated sera proteomics and glycomics. J Proteome Res. 2008; 7: 3293-3303. http://dx.doi.org/10.1021/pr800093b.
32. Lu DY, Xu J, Xu B, Zhou AM. Influence of several antineoplastic drugs on serum sialic acids of mice bearing tumors. Chin Biochem J. 1993; 9: 626-630.
33. Lu DY, Cao JY. Structural aberration of cellular sialic acids and their functions in cancer. J Shanghai Univ (Eng). 2001; 5: 164-170. http://dx.doi.org/10.1007/s11741-001-0016-6.
34. Liu J, Yang SL, Xu B. Characteristics of the interaction of lycobetaine with DNA. Acta Pharmacol Sin. 1989; 10: 437-442. http://www.ncbi.nlm.nih.gov/pubmed/2618733.
35. Abde-Hamid NM, Morsy MA. Novel biochemical pathways for 5-fluororacil in managing experimental hepatocellular carcinoma in rats. J Membrane Biol. 2010; 234: 29-34. http://dx.doi.org/10.1007/s00232-010-9236-7.
36. Peracaula R, Tabares G, Lopez-Ferrer A, Brossmer R, de Bolos C, de Llorens R. Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells. Glycoconjugate J. 2005; 22: 135-144. http://dx.doi.org/10.1007/s10719-005-0734-2.
37. Miyagi T, Wada T, Yamaguchi K, Tata K. Sialidase and malignancy: a minireview. Glycoconjugate J. 2004; 20: 189-198. http://dx.doi.org/10.1023/B:GLYC.0000024250.48506.bf.
38. Miyagi T, Wada T, Yamaguchi K, Shiozaki K, Sato I, Kakugawa Y, Yamanami H, Fujiya T. Human sialidase as a cancer marker. Proteomics. 2008; 8: 3303-3311. http://dx.doi.org/10.1002/pmic.200800248.
39. Chiang CH, Wang CH, Chang HC, More SV, Li WS, Hung WC. A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signal. J Cell Physiol. 2010; 223: 492-499. http://dx.doi.org/10.1002/jcp.22068.
40. Thejass P, Kuttan G. Antimetastatic activity of Sulforaphane. Life Sci. 2006; 78: 3043-3050. http://dx.doi.org/10.1016/j.lfs.2005.12.038.
41. Lee SJ, Chung IM, Kim MY, Park KD, Park WH, Moon HI. Inhibition of lung metastasis in mice by Oligonol. Phytother Res. 2009; 23: 1043-1046. http://dx.doi.org/10.1002/ptr.2810.
42. Higashi H, Hirabayashi Y, Fukui Y, Naiki M, Matsumoto M, Ueda S, Kato S. Characterization of N-glycolylneuraminic acid containing gangliosides as tumor-associated Hanganutziu Deicher antigen in human colon cancer. Cancer Res. 1985; 45: 3796-3802. http://www.ncbi.nlm.nih.gov/pubmed/3874688.
43. Kawai T, Kato A, Higashi H, Kato S, Naiki M. Quantitative determination of N-glycolyl-neuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry. Cancer Res. 1991; 51: 1242-1246. http://www.ncbi.nlm.nih.gov/pubmed/1997165.
44. Kwak DH, Ryu JS, Kim CH, Ko K, Ma JY, Hwang KA, Choo YK. Relations between ganglioside expression and anti-cancer effects of the monoclonal antibody against epithelial cell adhesion molecule in colon cancer. Exp Mol Med. 2011; 43: 693-701. http://dx.doi.org/10.3858/emm.2011.43.12.080.
45. Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood. 2010; 115: 4778-4786. http://dx.doi.org/10.1182/blood-2009-12-257386.
46. Sackstein R. Hitting the sweet spot for lymphoma. Blood. 2010; 115: 4626-4627. http://dx.doi.org/10.1182/blood-2010-03-272955.
47. Jayant S, Khandare JJ, Wang Y, Singh AP, Vorsa N, Minko T. Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment. Pharm Res. 2007; 24: 2120-2130. http://dx.doi.org/10.1007/s11095-007-9406-1.
48. Miles D, Roche H. Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK, Theratope Study Group. Phase III multicenter clinical trial of the sialy-TN(STn)-keyhole limpet hemocycenin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011, 16: 1092-1100. http://dx.doi.org/10.1634/theoncologist.2010-0307.
49. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003; 3 (Suppl 4): S139-S143. http://www.ncbi.nlm.nih.gov/pubmed/12620151.
50. st century: coming developments in glycobiology. Glycoconjugate J. 2003; 19: 161-163. http://dx.doi.org/10.1023/A:1024275322537.
51. Lu DY, Chen XL, Ding J. Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment. Med Hypotheses. 2006; 66: 45-51. http://dx.doi.org/10.1016/j.mehy.2005.07.023.
52. Vetvicka V, Fusek M. Procathepsin D as a tumor marker, anti-cancer drug or screening agent. Anticancer Agents Med Chem. 2012; 12: 172-175. http://www.ncbi.nlm.nih.gov/pubmed/22292775.
53. Lu DY, Chen XL, Ding J. Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy. Med Hypotheses. 2007; 68: 188-193. http://dx.doi.org/10.1016/j.mehy.2006.06.045.
54. Lu DY, Lu TR, Ding J. Cell biological manifestations of Bisdioxopiperazines: treatment of human tumor cell lines in culture. Anticancer Agents Med Chem. 2010; 10: 657-660. http://www.ncbi.nlm.nih.gov/pubmed/21235436.